Serum magnesium levels as related to symptomatic vasospasm and outcome following aneurysmal subarachnoid hemorrhage

被引:17
|
作者
Collignon, FP
Friedman, JA
Piepgras, DG
Pichelmann, MA
McIver, JI
Toussaint, LG
McClelland, RL
机构
[1] Dartmouth Hitchcock Med Ctr, Neurosurg Sect, Lebanon, NH 03766 USA
[2] Mayo Clin, Dept Neurol Surg, Rochester, MN USA
[3] Mayo Clin, Dept Biostat, Rochester, MN USA
关键词
magnesium; subarachnoid hemorrhage; aneurysm; vasospasm; stroke; cerebrovascular;
D O I
10.1385/NCC:1:4:441
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Introduction: Recent evidence suggests that magnesium may be neuroprotective in the setting of cerebral ischemia, and therapeutic magnesium infusion has been proposed for prophylaxis and treatment of delayed ischemic neurological deficit (DIND) resulting from vasospasm in patients with aneurysmal subarachnoid hemorrhage (SAH). We studied the association between serum magnesium levels, the development of DIND, and the outcomes of patients with SAH. Methods: We studied 128 consecutive patients with aneurysmal SAH treated at our institution between 1990 and 1997 who had a serum magnesium level measured at least once during the acute phase of their hospitalization. Delayed ischemic neurological deficit was defined as severe (major focal deficit or coma), moderate (incomplete focal deficit or decreased sensorium without coma), or none. Results: There was no significant difference in mean, minimum, or maximum serum magnesium levels between patients with and without DIND (1.93,1.83, 2.02 versus 1.91, 1.84, 1.97 mg/dL, respectively). Similarly, no difference was found in mean serum magnesium levels among patients with severe (1.94 mg/dL), moderate (1.92 mg/dL), or no DIND (1.91 mg/dL). Analyses of serum magnesium levels before (0-4 days following SAH), during (4-14 days following SAH), and after (greater than 14 days following SAH) the period of highest risk for vasospasm revealed no association with the development or severity of DIND. Permanent deficit or death resulting from vasospasm and Glasgow Outcome Scale score at longest follow-up were similarly unaffected by serum magnesium levels overall or during any time interval. Forty (31.5%) patients were hypomagnesemic (less than 1.7 mg/dL) during hospitalization, but no difference in outcome (p = 0.185) or development of DIND (p = 0.785) was found when compared to patients with normal (1.7-2.1 mg/dL) or high (greater than 2.1 mg/dL) magnesium serum levels. Conclusion: We identified no relationship between serum magnesium levels and the development of DIND or outcome following aneurysmal SAIL Based on these data, magnesium supplementation to normal or high-normal physiological ranges seems unlikely to be beneficial for DIND resulting from vasospasm. However, no inference can be made regarding the value of therapeutic infusion of magnesium to supraphysiological levels.
引用
收藏
页码:441 / 448
页数:8
相关论文
共 50 条
  • [41] Magnesium Sulfate Therapy for Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage
    Akdemir, Hidayet
    Kulaksizoglu, E. Onur
    Tucer, Buelent
    Menkue, Ahmet
    Postalci, Luetfue
    Guenaldi, Oemuer
    NEUROSURGERY QUARTERLY, 2009, 19 (01) : 35 - 39
  • [42] Hypotension is related to cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage
    Gentile, AM
    Spegiorin, MA
    Polachini, CA
    Tostes, M
    Spotti, AR
    Lobo, SMA
    INTENSIVE CARE MEDICINE, 2003, 29 : S183 - S183
  • [43] Effect of transluminal angioplasty on cerebral blood flow in the management of symptomatic vasospasm following aneurysmal subarachnoid hemorrhage
    Firlik, AD
    Kaufmann, AM
    Jungreis, CA
    Yonas, H
    JOURNAL OF NEUROSURGERY, 1997, 86 (05) : 830 - 839
  • [44] CEREBRAL VASOSPASM IN ANEURYSMAL SUBARACHNOID HEMORRHAGE
    HIRSH, LF
    POSTGRADUATE MEDICINE, 1981, 69 (04) : 71 - &
  • [45] Delayed Vasospasm in Aneurysmal Subarachnoid Hemorrhage
    Tulamo, Riikka
    Niemela, Mika
    Hernesniemi, Juha
    WORLD NEUROSURGERY, 2012, 77 (01) : 39 - 41
  • [46] Decreased Serum Sodium Levels Predict Symptomatic Vasospasm in Patients With Subarachnoid Hemorrhage.
    Uozumi, Yoichi
    Mizobe, Takashi
    Miyamoto, Hirohito
    Tatsumi, Shotaro
    Nakamura, Mitsugu
    Kohmura, Eiji
    STROKE, 2019, 50
  • [47] Monocyte chemoattractant protein-1 predicts outcome and vasospasm following aneurysmal subarachnoid hemorrhage
    Kim, Grace H.
    Kellner, Christopher P.
    Hahn, David K.
    Desantis, Brianna M.
    Musabbir, Muhith
    Starke, Robert M.
    Rynkowski, Michal
    Komotar, Ricardo J.
    Otten, Marc L.
    Sciacca, Robert
    Schmidt, J. Michael
    Mayer, Stephan A.
    Connolly, E. Sander, Jr.
    JOURNAL OF NEUROSURGERY, 2008, 109 (01) : 38 - 43
  • [48] Symptomatic vasospasm: Predictors and effect on outcome after subarachnoid hemorrhage
    Frontera, Jennifer A.
    Fernandez, Andres
    Schmidt, J. M.
    Badjatia, Neeraj
    Palestrant, David
    Parra, Augusto
    Wartenberg, Katja E.
    Rincon, Fred
    Mayer, Stephan A.
    STROKE, 2007, 38 (02) : 605 - 605
  • [49] Symptomatic Cerebral Hyperperfusion After Cerebral Vasospasm Associated with Aneurysmal Subarachnoid Hemorrhage
    Sakata, Hiroyuki
    Endo, Hidenori
    Fujimura, Miki
    Niizuma, Kuniyasu
    Tominaga, Teiji
    WORLD NEUROSURGERY, 2020, 137 : 379 - 383
  • [50] Early identification of patients at risk for symptomatic vasospasm after aneurysmal subarachnoid hemorrhage
    Qureshi, AI
    Sung, GY
    Razumovsky, AY
    Lane, K
    Straw, RN
    Ulatowski, JA
    CRITICAL CARE MEDICINE, 2000, 28 (04) : 984 - 990